TherapeuticsMD, Inc.

Company Overview

Business Model: TherapeuticsMD, Inc. transitioned in December 2022 to operate as a pharmaceutical royalty company. Its primary revenue is generated from royalties on products licensed to pharmaceutical organizations that manage commercialization in relevant territories. This includes an exclusive license granted to Mayne Pharma LLC for IMVEXXY, BIJUVA, and prescription prenatal vitamin products (BocaGreenMD and vitaMedMD brands) in the United States and its possessions and territories, as well as the assignment of an exclusive license to Mayne Pharma LLC for ANNOVERA in the same regions. The Company also holds license agreements with Knight Therapeutics Inc. and Theramex HQ UK Limited for IMVEXXY and BIJUVA outside the United States.

Market Position: The Company's licensed product portfolio focuses on women's healthcare, including IMVEXXY (for moderate-to-severe dyspareunia due to menopause), BIJUVA (the first and only FDA-approved bioidentical hormone therapy combination for moderate-to-severe vasomotor symptoms due to menopause), ANNOVERA (a one-year patient-controlled contraceptive vaginal system), and prescription prenatal vitamins. TherapeuticsMD, Inc. relies entirely on its licensees for commercialization, manufacturing, and research and development. The pharmaceutical and dietary supplement industries are intensely competitive, with competition from major multinational pharmaceutical, biotechnology, specialty pharmaceutical, and generic drug companies. The Company's competitive position is primarily protected by its intellectual property portfolio, including domestic and foreign patents, with Mayne Pharma LLC responsible for the prosecution and enforcement of U.S. patents and trademarks for the licensed products.

Recent Strategic Developments:

• December 2022 Transformation: Completed a transaction with Mayne Pharma LLC, receiving $140.0 million cash at closing, approximately $12.1 million for net working capital, and $1.0 million for prepaid royalties. The agreement includes contingent milestone payments of $5.0 million, $10.0 million, and $15.0 million if aggregate U.S. net sales of all Products reach $100.0 million, $200.0 million, and $300.0 million, respectively. Royalties are set at 8.0% on the first $80.0 million in annual net sales and 7.5% on sales above $80.0 million for 20 years, with a decrease to 2.0% upon patent expiration or generic launch. Minimum annual royalties of $3.0 million per year for 12 years, adjusted for 3% annual inflation, are also part of the agreement.
• International License Transfer: In December 2024, the right to commercialize IMVEXXY and BIJUVA in Israel was transferred from Knight Therapeutics Inc. to Theramex HQ UK Limited.
• Capital Raising: In May 2023, TherapeuticsMD, Inc. entered into a Subscription Agreement with Rubric Capital Management LP to sell up to 5,000,000 shares of common stock for up to $5,000,000. As of December 31, 2024, $3.15 million in gross proceeds had been received from drawdowns in 2023, with no drawdowns in 2024.
• Ongoing Disputes: The Company is engaged in ongoing disputes with Mayne Pharma LLC regarding net working capital allowances for payer rebates, wholesale distributor fees, and returns, as well as certain indemnification demands. The outcome of these matters is currently uncertain.
• Acquisition of Licensee Parent: In February 2025, Mayne Pharma Group Limited (parent of Mayne Pharma LLC) announced an agreement to be acquired by Cosette Pharmaceuticals, Inc., which could have an adverse effect on TherapeuticsMD, Inc.'s business, operations, and financial condition.

Geographic Footprint: The Company's primary market for licensed products is the United States, through Mayne Pharma LLC. Internationally, IMVEXXY and BIJUVA are licensed to Knight Therapeutics Inc. in Canada and to Theramex HQ UK Limited in Europe and other regions (excluding Canada and Israel). In 2024, U.S. license and service revenue was $1,123 thousand, while non-U.S. revenue was $638 thousand.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: Not applicable (revenue is license/royalty, no cost of goods sold).
• Operating Margin: -270.3%
• Net Margin: -123.8%

Investment in Growth:

• R&D Expenditure: TherapeuticsMD, Inc. no longer conducts research and development activities as of December 30, 2022.
• Capital Expenditures: Not explicitly disclosed.
• Strategic Investments: $2,334 thousand in legal costs for the IMVEXXY Paragraph IV legal proceeding were capitalized as prepaid expenses and other current assets as of December 31, 2024, to be reclassified to patents upon successful conclusion.

Business Segment Analysis

TherapeuticsMD, Inc. manages and operates as one business segment, focused on collecting royalties from licensing its products. The Company does not prepare discrete financial information for separate products.

IMVEXXY (estradiol vaginal inserts)

Financial Performance:

• License sales through Mayne Pharma LLC (U.S.): Included in the $1,123 thousand license revenue from Mayne Pharma LLC in 2024 (combined with BIJUVA and prenatal vitamins).
• License sales through Knight Therapeutics Inc. (Canada/Israel): Included in the $195 thousand license revenue from Knight Therapeutics Inc. in 2024 (combined with BIJUVA).
• Key Growth Drivers: Commercialization efforts by Mayne Pharma LLC in the U.S. and Knight Therapeutics Inc. in Canada (commercialization began in 2024). Theramex HQ UK Limited assumed commercialization rights in Israel in December 2024.

Product Portfolio:

• 4-μg and 10-μg estradiol vaginal inserts for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy due to menopause.

Market Dynamics:

• Subject to ongoing patent infringement litigation. In February 2020, Teva Pharmaceuticals USA, Inc. filed a Paragraph IV ANDA for a generic version, leading to a lawsuit by TherapeuticsMD, Inc. In June 2024, Sun Pharma Inc. also filed a Paragraph IV ANDA for a generic version, resulting in a joint patent infringement complaint by TherapeuticsMD, Inc. and Mayne Pharma LLC. The IMVEXXY Patents expire in 2032 or 2033. Mayne Pharma LLC is responsible for the enforcement and costs of this litigation.

BIJUVA (estradiol and progesterone) capsules

Financial Performance:

• License sales through Theramex HQ UK Limited (ex-U.S., ex-Canada/Israel): $443 thousand in 2024, an increase from $268 thousand in 2023.
• License sales through Knight Therapeutics Inc. (Canada/Israel): Included in the $195 thousand license revenue from Knight Therapeutics Inc. in 2024 (combined with IMVEXXY).
• License sales through Mayne Pharma LLC (U.S.): Included in the $1,123 thousand license revenue from Mayne Pharma LLC in 2024 (combined with IMVEXXY and prenatal vitamins).
• Key Growth Drivers: Commercialization efforts by Theramex HQ UK Limited in certain European countries (began in 2021) and Knight Therapeutics Inc. in Canada (began in 2024). Theramex HQ UK Limited assumed commercialization rights in Israel in December 2024.

Product Portfolio:

• 1 mg/100 mg capsules, the first and only FDA-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) due to menopause in women with a uterus.

Market Dynamics:

• In December 2021, TherapeuticsMD, Inc. settled patent litigation with Amneal Pharmaceuticals, Inc., granting a non-exclusive, royalty-free license for Amneal Pharmaceuticals, Inc.'s generic BIJUVA in the U.S. commencing in May 2032.

ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

Financial Performance:

• Royalty sales recognized as other income: $1,083 thousand in 2024, an increase from $490 thousand in 2023.
• Key Growth Drivers: Commercialization by Mayne Pharma LLC in the United States.

Product Portfolio:

• A one-year ring-shaped contraceptive vaginal system (CVS), the first and only patient-controlled, procedure-free, reversible prescription contraceptive that can prevent pregnancy for up to 13 cycles (one year).

Market Dynamics:

• The exclusive license to commercialize ANNOVERA in the United States was assigned to Mayne Pharma LLC.
• Subject to four non-closed post-marketing studies required by the FDA, conducted by Population Council and Mayne Pharma LLC. The FDA indicated in July 2021 that one study was not fulfilled to its satisfaction, and two others had delayed submission deadlines.

Prenatal Vitamin Products (BocaGreenMD and vitaMedMD brands)

Financial Performance:

• License sales through Mayne Pharma LLC (U.S.): Included in the $1,123 thousand license revenue from Mayne Pharma LLC in 2024 (combined with IMVEXXY and BIJUVA).
• Key Growth Drivers: Commercialization by Mayne Pharma LLC in the United States.

Product Portfolio:

• Prescription prenatal vitamin product lines under the vitaMedMD brand name and authorized generic formulations under the BocaGreenMD prenatal name.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed.
• Dividend Payments: TherapeuticsMD, Inc. has never declared or paid cash dividends on its common stock and does not anticipate doing so in the foreseeable future, intending to retain any future earnings for business operations.
• Dividend Yield: 0.0%
• Future Capital Return Commitments: None explicitly stated.

Balance Sheet Position:

• Cash and Equivalents: $5,059 thousand as of December 31, 2024.
• Total Debt: No debt reported on the balance sheet. All obligations under the Financing Agreement were repaid and terminated in December 2022.
• Net Cash Position: $5,059 thousand as of December 31, 2024.
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Not applicable as no debt is reported.

Cash Flow Generation:

• Operating Cash Flow: $1,170 thousand in 2024, a significant improvement from $(23,081) thousand in 2023.
• Free Cash Flow: Not explicitly stated, but positive operating cash flow indicates strong cash generation from continuing operations.
• Cash Conversion Metrics: Not explicitly stated.

Operational Excellence

Production & Service Model: TherapeuticsMD, Inc. ceased direct commercial operations and research and development activities as of December 30, 2022, transforming into a pharmaceutical royalty company. All manufacturing responsibility for its licensed and assigned products has been transferred to its licensees. The Company operates from a fully remote environment and engages external consultants to support partner relationships and assist with financial, IT, legal, and regulatory matters, as well as the wind-down of historical business operations.

Supply Chain Architecture: Key Suppliers & Partners:

• Manufacturing Partners: The Company's licensees rely on third-party contract manufacturing organizations (CMOs). These include Catalent Pharma Solutions, LLC for IMVEXXY and BIJUVA, and QPharma AB (now Sever Pharma Solutions) for ANNOVERA. Lang previously supplied vitaMedMD and BocaGreenMD products.
• Technology Partners: Population Council is the original licensor of ANNOVERA.

Facility Network:

• Headquarters: Boca Raton, Florida. The Company has subleased 41,418 square feet of its headquarters and is in the process of subleasing the remaining 21,330 square feet due to its shift to a pharmaceutical royalty business model and employee terminations.
• Manufacturing: Transferred to licensees.
• Research & Development: No longer conducts R&D.
• Distribution: Relies on licensees' distribution channels.

Operational Metrics:

• Not explicitly disclosed for the royalty business model.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Channel Partners: TherapeuticsMD, Inc. relies entirely on its licensees—Mayne Pharma LLC, Knight Therapeutics Inc., and Theramex HQ UK Limited—for the commercialization and distribution of its products.
• Direct Sales: Not applicable for TherapeuticsMD, Inc. in its current royalty-based business model.
• Digital Platforms: Not applicable for TherapeuticsMD, Inc. in its current royalty-based business model.

Customer Portfolio: Enterprise Customers:

• Licensees: The Company's primary "customers" are its licensing partners: Mayne Pharma LLC (for U.S. rights), Knight Therapeutics Inc. (for Canada), and Theramex HQ UK Limited (for ex-U.S., ex-Canada/Israel).
• Customer Concentration: For the year ended December 31, 2024, 100% of license revenue was derived from Mayne Pharma LLC, Theramex HQ UK Limited, and Knight Therapeutics Inc.

Geographic Revenue Distribution:

• United States: $1,123 thousand (63.8% of total license revenue) in 2024.
• Non-U.S.: $638 thousand (36.2% of total license revenue) in 2024.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The pharmaceutical and dietary supplement industries are characterized by intense competition and rapid technological change. Market acceptance and sales of products are highly dependent on physician and payer acceptance, cost-effectiveness relative to alternatives, ease of administration, efficacy of competitive drugs, and the effectiveness of licensee sales and marketing efforts. The industry is subject to extensive and costly government regulation by agencies such as the FDA, CMS, OIG, DOJ, and various state and foreign authorities. There are ongoing pricing pressures from managed healthcare, health maintenance organizations, government scrutiny, and legislative proposals aimed at controlling pharmaceutical costs.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: The Company's licensed products face significant competition from major multinational pharmaceutical and dietary supplement companies, established biotechnology companies, specialty pharmaceutical companies, and generic drug manufacturers.

• Teva Pharmaceuticals USA, Inc.: Filed a Paragraph IV ANDA for a generic version of IMVEXXY, leading to ongoing patent infringement litigation.
• Sun Pharma Inc.: Filed a Paragraph IV ANDA for a generic version of IMVEXXY, leading to ongoing patent infringement litigation.
• Amneal Pharmaceuticals, Inc.: Settled patent litigation for a generic version of BIJUVA, with a U.S. launch authorized for May 2032.

Emerging Competitive Threats: The potential introduction of generic versions of IMVEXXY and other licensed products, as well as new entrants, disruptive technologies, and alternative solutions, pose ongoing competitive threats.

Competitive Response Strategy: TherapeuticsMD, Inc. relies on Mayne Pharma LLC to prosecute, enforce, and defend its intellectual property rights for U.S. licensed products. The Company actively protects its intellectual property through patents, trademarks, trade secrets, and contractual restrictions.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Royalty Revenue Dependence: All revenue is derived from royalties, making the Company highly dependent on the sales performance and commercialization efforts of its licensees.
• Licensee Performance: The ability of licensees (Mayne Pharma LLC, Knight Therapeutics Inc., Theramex HQ UK Limited) to maintain or increase product sales is critical and subject to various risks, including competition, supply issues, regulatory changes, and healthcare policy shifts.
• Competitive Landscape: Significant competition from branded and generic products, including ongoing Paragraph IV challenges for IMVEXXY, could reduce royalty revenues.
• Healthcare Policy & Reimbursement: Changes in healthcare laws, drug pricing, rebates, and reimbursement policies by government programs and third-party payers could adversely affect the profitability of licensed product sales.
• Mayne Pharma Group Limited Acquisition: The pending acquisition of Mayne Pharma Group Limited by Cosette Pharmaceuticals, Inc. introduces uncertainty and potential adverse effects on business relationships and licensed product sales.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Third-Party Manufacturing Reliance: The Company's licensees rely on third-party CMOs for manufacturing. Any failure by these CMOs to comply with cGMPs, supply raw materials, or meet production demands could disrupt product supply and reduce royalties.
• Post-Approval Study Compliance: Failure by Mayne Pharma LLC or Population Council to fulfill FDA-mandated post-approval studies for ANNOVERA could lead to regulatory actions and limit product sales.
• Winding Down Operations: Significant costs and potential unforeseen liabilities are associated with the ongoing wind-down of historical commercial operations.
• Property Sublease: Risks include inability to sublease remaining headquarters space on favorable terms or subtenant defaults, leading to unanticipated payment obligations.

Financial & Regulatory Risks

Market & Financial Risks:

• Going Concern Uncertainty: The Company's current liquidity position and negative cash flow raise substantial doubt about its ability to continue as a going concern for the next twelve months.
• Net Working Capital Disputes: Ongoing disputes with Mayne Pharma LLC regarding net working capital adjustments (payer rebates, wholesale distributor fees, returns) and indemnification demands could materially impact financial condition.
• Capital Raising: The need for additional capital may lead to equity or debt financing, potentially diluting existing stockholders.
• Cash Concentration: Cash balances held at financial institutions may exceed federally insured limits, posing a risk of loss in case of bank failure.
• Product Liability: Inherent risk of product liability claims, particularly for hormone therapy and contraceptive products, could result in substantial liabilities and divert resources.
• Tax Strategy & NOLs: The Company has a federal net operating loss (NOL) carryforward of $579.0 million, but its utilization is limited by Section 382 ownership changes and CARES Act provisions, and a full valuation allowance is in place.

Regulatory & Compliance Risks:

• Extensive Government Regulation: Products and licensees are subject to rigorous and costly regulation by numerous federal, state, and foreign authorities, including the FDA, CMS, and laws pertaining to fraud and abuse, pricing, and data privacy. Non-compliance could result in significant penalties, fines, and operational restrictions.
• Intellectual Property Enforcement: Reliance on Mayne Pharma LLC to enforce U.S. patents means the Company cannot assure successful defense against infringement claims or the prevention of generic product introductions.
• Data Privacy: Compliance with data protection laws like GDPR and other regulations imposes significant obligations and potential penalties for non-compliance or data breaches.

Innovation & Technology Leadership

Research & Development Focus: TherapeuticsMD, Inc. no longer conducts any research and development activities as of December 30, 2022, having transitioned to a pharmaceutical royalty company.

Intellectual Property Portfolio:

• Patent Strategy: The Company relies on a combination of know-how, trade secrets, patents, trademarks, and contractual restrictions to protect its competitive position. It holds numerous domestic and foreign patents covering its licensed products, including Orange Book listed patents for BIJUVA and IMVEXXY.
• Licensing Programs: The Company's intellectual property is licensed to Mayne Pharma LLC (U.S.), Knight Therapeutics Inc. (Canada), and Theramex HQ UK Limited (ex-U.S., ex-Canada/Israel).
• IP Litigation: TherapeuticsMD, Inc. is involved in patent infringement lawsuits against Teva Pharmaceuticals USA, Inc. and Sun Pharma Inc. concerning Paragraph IV ANDAs for generic IMVEXXY. Mayne Pharma LLC is responsible for the prosecution and enforcement of the Company's U.S. patent and trademark portfolio and the costs of such litigation.
• Risk: Patents may be challenged, found invalid or unenforceable, or circumvented by competitors, which could adversely affect royalty revenues.

Technology Partnerships:

• Strategic Alliances: The Population Council is the original licensor of ANNOVERA, with the exclusive U.S. license assigned to Mayne Pharma LLC.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: TherapeuticsMD, Inc. experienced significant turnover in its executive team in December 2022, with most top executives terminated. Marlan D. Walker is currently the Company's sole full-time employee and Chief Executive Officer. The Company relies on external consultants for various functions. The dependence on a single employee, who is at-will, poses a risk to business continuity and operations.

Board Composition: Not explicitly detailed in the provided text, beyond mentioning Justin Roberts (Partner of Rubric Capital Management LP) as a director.

Human Capital Strategy

Workforce Composition:

• Total Employees: As of December 31, 2024, TherapeuticsMD, Inc. employed one full-time employee, primarily engaged in an executive position (Chief Executive Officer).
• Geographic Distribution: Not specified for the single employee.
• Skill Mix: The Company relies on external consultants for specialized support in financial, IT, legal, and regulatory matters.

Talent Management: Acquisition & Retention:

• Hiring Strategy: The Company engages external consultants to support its operations.
• Retention Metrics: Not applicable for a single employee.
• Employee Value Proposition: Not applicable for a single employee.

Diversity & Development:

• Not applicable for a single employee.
• Culture & Engagement: Not applicable for a single employee.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: The pharmaceutical markets in which TherapeuticsMD, Inc. licenses its products are not subject to seasonal sales fluctuations.
• Economic Sensitivity: License revenues for the first quarter of each year can be negatively affected by the annual reset of high-deductible commercial insurance plans.
• Industry Cycles: Not explicitly detailed.

Planning & Forecasting:

• Not explicitly detailed.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• FDA Regulation: The Company's licensed products are subject to extensive and rigorous regulation by the FDA under the Federal Food, Drug, and Cosmetic Act (FDCA), including requirements for new drug applications (NDAs), current Good Manufacturing Practices (cGMPs), post-approval studies, advertising and promotional labeling, and risk evaluation and mitigation strategies (REMS).
• Healthcare Laws: Licensees are subject to federal and state healthcare laws, including the Anti-Kickback Statute (AKS), federal civil and criminal false claims laws, the Health Insurance Portability and Accountability Act (HIPAA) (as amended by HITECH), the Physician Payments Sunshine Act, and state-specific anti-kickback and false claims laws.
• Drug Supply Chain Security Act (DSCSA): Requires compliance with product tracing and supply chain standards for prescription pharmaceutical products.
• International Compliance: Products marketed outside the U.S. are subject to foreign government regulations, which may include separate regulatory approvals, pricing controls, and pharmacovigilance reporting requirements.

Trade & Export Controls:

• Export Restrictions: Not explicitly detailed beyond general compliance.
• Sanctions Compliance: Not explicitly detailed beyond general compliance.

Legal Proceedings:

• IMVEXXY Patent Litigation: TherapeuticsMD, Inc. and Mayne Pharma LLC are involved in patent infringement lawsuits against Teva Pharmaceuticals USA, Inc. and Sun Pharma Inc. in the U.S. District Court for the District of New Jersey, challenging Paragraph IV ANDAs for generic IMVEXXY. Mayne Pharma LLC is responsible for the enforcement and costs of this litigation.
• BIJUVA Patent Settlement: Litigation with Amneal Pharmaceuticals, Inc. regarding a generic BIJUVA ANDA was settled in December 2021, allowing for a generic launch in May 2032.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: The Company recorded a benefit for income taxes of 1.3% in 2024 and 0.5% in 2023.
• Geographic Tax Planning: Not explicitly detailed.
• Tax Reform Impact: As of December 31, 2024, TherapeuticsMD, Inc. had a federal net operating loss (NOL) carryforward of $579.0 million. Approximately $22.7 million of federal NOLs can be carried forward for 20 years (expiring starting 2035), while the remaining $557 million can be carried forward indefinitely. The Company experienced an ownership change in 2022, which limits the utilization of NOL carryforwards under IRC Section 382. Additionally, the CARES Act limits NOL deductions to 80% of taxable income for NOLs generated in taxable years beginning in 2021. A full valuation allowance has been established against the Company's deferred tax assets.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: TherapeuticsMD, Inc. maintains general liability insurance and clinical trial liability insurance for its products. The Company also carries cybersecurity insurance to protect against breaches and provide resources in the event of an incident.
• Risk Transfer Mechanisms: Not explicitly detailed beyond insurance.